Enhancing HER2-targeted therapy for resistant breast cancer
Official title: Enhancing HER2-targeted therapy for refractory HER2-positive breast cancer
Funded at Lsu Health Sciences Center · NIH-11457632 · Data updated 2026-11-12
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | September 4, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $521,265 |
| NIH project number | 1R01CA317243-01 |
| Project ID | NIH-11457632 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with HER2-positive breast cancer, especially those showing resistance to Herceptin-based regimens.
✕Less likely to help
Patients without HER2-positive breast cancer or those not facing Herceptin resistance may not directly benefit.
What this research studies
If you have HER2-positive breast cancer and have not fully responded to Herceptin, this project looks at why resistance happens and tests new approaches to make therapies work better. Researchers are focusing on the IGF-1R pathway and related molecular signals that may drive resistance, with the goal of identifying targets to improve response. The work involves studying tumor biology and blood-based markers to understand who might benefit from additional treatments. The aim is to translate findings into new strategies that could be added to existing HER2-directed care.
Why it matters
Potential benefit: If successful, the research could lead to new combination therapies or biomarkers that help predict who will respond to HER2-directed treatment and improve outcomes.
How similar studies have gone: Previous work has linked IGF-1R signaling to Herceptin resistance; this project advances understanding and potential therapies in this area.
Where this research is happening
-
Lsu Health Sciences Center
New Orleans, United States Active
Researchers
- Principal investigator: Liu, Bolin — Lsu Health Sciences Center
- Study coordinator: Liu, Bolin
Related research
Other NIH-funded projects on the same topics.
-
Prolactin signaling and brain metastasis in HER2-positive breast cancer
Researchers are studying how prolactin signals help HER2-positive breast cancer cells grow in the brain, with the goal of finding new ideas to prevent brain metastases.
-
XoLacta adjuvant therapy to reduce radiation side effects during HER2-positive breast cancer treatment
A new milk-derived therapy called XoLacta aims to lessen radiation-related side effects for people undergoing treatment for HER2-positive breast cancer.
-
Ig repertoire in tumor-infiltrating B cells in metastatic HER2-positive breast cancer (mouse model)
Scientists will study how antibodies from immune cells inside HER2-positive breast tumors behave in a mouse model to understand potential new ways to fight the cancer.
-
Overcoming Resistance to Targeted Therapy in Breast Cancer
Researchers are studying why some breast cancers stop responding to targeted therapies and what can be done to overcome this resistance.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Autophagy and vesicle trafficking linked to HER2+ breast cancer progression
A cancer research project aims to understand how cell recycling processes and vesicle movement affect HER2-positive breast cancer, with potential implications for metastasis and resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.